1 day Ago By Defense World Staff
Renaissance Technologies LLC lifted its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) by 13.4% during the 4th quarter, according to its most recent disclosure with the SEC.
The institutional investor owned 1,105,591 shares of the company’s stock after buying an additional 130,938 shares during the quarter. Renaissance Technologies LLC owned approximately 2.03% of Spero Therapeutics worth $1,139,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of the stock. Monimus Capital Management LP purchased a new stake in shares of Spero Therapeutics in the fourth quarter worth about $320,000. JPMorgan Chase & Co.
increased its stake in Spero Therapeutics by 26,011.9% in the 4th quarter. JPMorgan Chase & Co.
now owns 61,624 shares of the company’s stock worth $63,000 after acquiring an additional 61,388 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Spero Therapeutics by 7.8% during the 4th quarter.
ADAR1 Capital Management LLC now owns 801,277 shares of the company’s stock worth $825,000 after acquiring an additional 57,818 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Spero Therapeutics during the 4th quarter valued at approximately $51,000.
Finally, Virtu Financial LLC purchased a new position in shares of Spero Therapeutics in the fourth quarter valued at $47,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.
Spero Therapeutics Price PerformanceShares of SPRO stock opened at $0.67 on Wednesday. The company has a market cap of $37.
51 million, a PE ratio of 9.59 and a beta of 0.64.
Spero Therapeutics, Inc. has a 1 year low of $0.51 and a 1 year high of $1.
72. The stock’s 50 day simple moving average is $0.73 and its two-hundred day simple moving average is $0.
95. Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.
38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03).
Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%.
The company had revenue of $15.04 million during the quarter, compared to the consensus estimate of $12.40 million.
Equities research analysts expect that Spero Therapeutics, Inc. will post -1.2 EPS for the current year.
Wall Street Analysts Forecast GrowthSeparately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Spero Therapeutics in a research note on Thursday, January 30th.View Our Latest Research Report on Spero TherapeuticsInsider Buying and Selling at Spero TherapeuticsIn other news, CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction dated Wednesday, February 5th.
The shares were sold at an average price of $0.78, for a total value of $121,159.74.
Following the transaction, the chief executive officer now directly owns 1,736,883 shares in the company, valued at approximately $1,354,768.74. This represents a 8.
21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ankit Mahadevia sold 69,219 shares of Spero Therapeutics stock in a transaction dated Wednesday, February 5th.
The shares were sold at an average price of $0.78, for a total transaction of $53,990.82.
Following the sale, the director now owns 689,866 shares of the company’s stock, valued at $538,095.48. The trade was a 9.
12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 245,241 shares of company stock valued at $191,288 in the last quarter.
4.52% of the stock is owned by insiders. Spero Therapeutics Company Profile (Free Report)Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.Recommended StoriesFive stocks we like better than Spero TherapeuticsLow PE Growth Stocks: Unlocking Investment OpportunitiesDon’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetGrowth Investing: Should You Adopt This Investing Strategy in 2022?Coca-Cola Company Stock Can Bubble to New Highs This YearInsider Selling Explained: Can it Inform Your Investing Choices?3 Stocks Lifting 2025 Guidance Despite Market Jitters.
